

Cover Story
Conversation with The Cancer Letter
By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
The past six weeks have brought fundamental change in the way oncology drugs are being developed. At this unprecedented moment in oncopolitics, FDA, NCI, academic oncologists, advocates, and the industry are in agreement on how cancer therapies should be developed, tested and approved.
In Brief


Clinical Roundup


Trending Stories
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster
- Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines - Bonnie Addario, lung cancer survivor and advocate, dies at 77